|
"hsia t c"的相關文件
顯示項目 11-20 / 76 (共8頁)
<< < 1 2 3 4 5 6 7 8 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2022-06-27T07:00:29Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Ho C.-C.; Hsia T.-C.; Su K.-Y.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; CHONG-JEN YU; Yang P.-C.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:17Z |
Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients
|
Hsu K.-H.; Tseng J.-S.; Wang C.-L.; Yang T.-Y.; Tseng C.-H.; Chen H.-Y.; Chen K.-C.; Tsai C.-R.; Yang C.-T.; Yu S.-L.; Su K.-Y.; CHONG-JEN YU; Ho C.C.; Hsia T.-C.; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Yang P.-C.; Chen J.J.W.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:12Z |
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE study
|
Chang G.-C.; Tseng C.-H.; Hsu K.-H.; CHONG-JEN YU; Yang C.-T.; Chen K.-C.; Yang T.-Y.; Tseng J.-S.; Liu C.-Y.; Liao W.-Y.; Hsia T.-C.; Tu C.-Y.; Lin M.-C.; Tsai Y.-H.; Hsieh M.-J.; Wu W.-S.; Chen Y.-M. |
| 臺大學術典藏 |
2022-06-27T06:59:40Z |
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
|
Chen Y.-M.; Chih-Hsin Yang J.; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; Ho C.-C.; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2022-06-27T06:59:36Z |
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
|
Tan D.S.W.; Geater S.; CHONG-JEN YU; Tsai C.-M.; Hsia T.-C.; Chen J.; Lin M.-C.; Lu Y.; Sriuranpong V.; Yang C.-T.; Sen P.; Branle F.; Shi M.; Wu Y.-L. |
| 臺大學術典藏 |
2022-06-27T02:49:09Z |
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
|
Su P.-L.; Chang G.-C.; Hsiao S.-H.; Hsia T.-C.; Lin M.-C.; Lin M.-H.; JIN-YUAN SHIH; Yang C.-T.; Yang S.-H.; Chen Y.-M. |
| 臺大學術典藏 |
2022-06-27T02:49:08Z |
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
|
Popat S.; Hsia T.-C.; Hung J.-Y.; Jung H.A.; JIN-YUAN SHIH; Park C.K.; Lee S.H.; Okamoto T.; Ahn H.K.; Lee Y.C.; Sato Y.; Lee S.S.; Mascaux C.; Daoud H.; M?rten A.; Miura S. |
| 臺大學術典藏 |
2022-06-10T06:11:15Z |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
|
Perng R.-P.; Yang C.-H.; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; Yu C.-J.; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN; Kao W.-Y. |
| 國立成功大學 |
2022 |
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
|
Su, P.-L.;Chang, G.-C.;Hsiao, S.-H.;Hsia, T.-C.;Lin, M.-C.;Lin, M.-H.;Shih, J.-Y.;Yang, C.-T.;Yang, S.-H.;Chen, Y.-M. |
| 國立成功大學 |
2022 |
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
|
Lu, S.;Wang, Q.;Zhang, G.;Dong, X.;Yang, C.-T.;Song, Y.;Chang, G.-C.;Lu, Y.;Pan, H.;Chiu, Chiu C.-H.;Wang, Z.;Feng, J.;Zhou, J.;Xu, Xu X.;Guo, R.;Chen, J.;Yang, H.;Chen, Y.;Yu, Z.;Shiah, H.-S.;Wang, C.-C.;Yang, N.;Fang, J.;Wang, P.;Wang, K.;Hu, Y.;He, J.;Wang, Z.;Shi, J.;Chen, S.;Wu, Q.;Sun, C.;Li, C.;Wei, H.;Cheng, Y.;Su, W.-C.;Hsia, T.-C.;Cui, J.;Sun, Y.;Ou, S.-H.I.;Zhu, V.W.;Chih-Hsin, Yang J. |
顯示項目 11-20 / 76 (共8頁)
<< < 1 2 3 4 5 6 7 8 > >>
每頁顯示[10|25|50]項目
|
